We have located links that may give you full text access.
Anti-protein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis.
Rheumatology 2022 November 29
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease in which possible interstitial lung disease (ILD) is an extra-articular manifestation that carries significant morbidity and mortality. Rheumatoid Factors (RF) and anti-citrullinated protein antibodies (ACPA) are included in the RA classification criteria but prognostic and diagnostic biomarkers for disease endotyping and RA-ILD are lacking. Anti-protein arginine deiminase antibodies (anti-PAD) are a novel class of autoantibodies identified in RA. This study aimed to assess clinical features, ACPA, and anti-PAD antibodies in RA patients with articular involvement and ILD.
METHODS: We retrospectively collected joint erosions, space narrowing, clinical features, and lung involvement of a cohort of seventy-one patients fulfilling the 2010 ACR/EULAR RA classification criteria. Serum samples from these patients were tested for ACPA IgG (QUANTA Flash CCP3), and anti-PAD3 and anti-PAD4 IgG, measured with novel assays based on a particle-based multi-analyte technology (PMAT).
RESULTS: Anti-PAD4 antibodies were significantly associated with radiographic injury (p= 0.027) and erosions (p= 0.02). Similarly, ACPA levels were associated with erosive disease (p= 0.014). Anti-PAD3/4 double positive patients displayed more joint erosions than patients with anti-PAD4 antibodies only or negative for both (p= 0.014 and p= 0.037, respectively). RA-ILD (15.5%, 11/71 patients) was associated with older age (p< 0.001), shorter disease duration (p= 0.045) and less erosive disease (p= 0.0063). ACPA were elevated in RA-ILD, while anti-PAD4 were negatively associated (p= 0.043).
CONCLUSION: Anti-PAD4 and anti-PAD3 antibodies identify RA-patient with higher radiographic injury and bone erosions. In our cohort, ILD is associated with lower radiographic and erosive damage, as well as low levels of anti-PAD4 antibodies.
METHODS: We retrospectively collected joint erosions, space narrowing, clinical features, and lung involvement of a cohort of seventy-one patients fulfilling the 2010 ACR/EULAR RA classification criteria. Serum samples from these patients were tested for ACPA IgG (QUANTA Flash CCP3), and anti-PAD3 and anti-PAD4 IgG, measured with novel assays based on a particle-based multi-analyte technology (PMAT).
RESULTS: Anti-PAD4 antibodies were significantly associated with radiographic injury (p= 0.027) and erosions (p= 0.02). Similarly, ACPA levels were associated with erosive disease (p= 0.014). Anti-PAD3/4 double positive patients displayed more joint erosions than patients with anti-PAD4 antibodies only or negative for both (p= 0.014 and p= 0.037, respectively). RA-ILD (15.5%, 11/71 patients) was associated with older age (p< 0.001), shorter disease duration (p= 0.045) and less erosive disease (p= 0.0063). ACPA were elevated in RA-ILD, while anti-PAD4 were negatively associated (p= 0.043).
CONCLUSION: Anti-PAD4 and anti-PAD3 antibodies identify RA-patient with higher radiographic injury and bone erosions. In our cohort, ILD is associated with lower radiographic and erosive damage, as well as low levels of anti-PAD4 antibodies.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app